Lack of Epistatic Interaction of SNCA with APOE in Synucleinopathies

Short Running Title: No SNCA-APOE Interactions in PD, DLB and iRBD

Prabhjyot Saini ^{1,2}, Eric Yu ^{1,2}, Mehrdad A. Estiar ^{1,2,4}, Lynne Krohn ^{1,2}, Kheireddin Mufti ^{1,2}, Uladzislau Rudakou ^{1,2}, Jennifer A. Ruskey ^{1,3}, Farnaz Asayesh ^{1,3}, Sandra B. Laurent ^{1,3}, Dan Spiegelman ^{1,3}, Jean-François Trempe ³⁶, Timothy G. Quinnell ³³, Nicholas Oscroft ³³, Isabelle Arnulf ⁷, Jacques Y. Montplaisir ^{31,34}, Jean-François Gagnon ^{31,32}, Alex Desautels ^{31,33}, Yves Dauvilliers ⁸, Gian Luigi Gigli ^{29,30}, Mariarosaria Valente ^{29,30}, Francesco Janes ²⁹, Andrea Bernardini ²⁹, Karel Sonka ²⁵, David Kemlink ²⁵, Wolfgang Oertel ²⁴, Karri Kaivola¹⁷, International LBD Genomics Consortium, Annette Janzen ²⁴, Giuseppe Plazzi ^{13,14}, Elena Antelmi ¹⁶, Francesco Biscarini ¹³, Michela Figorilli ²⁶, Monica Puligheddu ²⁶, Brit Mollenhauer ^{22,23}, Claudia Trenkwalder ^{22,23}, Friederike Sixel-Döring ^{22,24}, Valérie Cochen De Cock ^{20,21}, Christelle Charley Monaca ¹¹, Donald Grosset ^{38,39}, Anna Heidbreder ¹⁷, Luigi Ferini-Strambi ¹⁵, Femke Dijkstra ^{27,28,37}, Mineke Viaene ^{27,28}, Beatriz Abril ¹², Bradley F. Boeve ¹⁸, Ronald B. Postuma ^{1,3}, Guy A. Rouleau ^{1,2}, Victoria Anselmi ⁸, Abubaker Ibrahim ⁹, Ambra Stefani ⁹, Birgit Högl ⁹, Michele T.M. Hu ^{5,6}, Sonja W. Scholz ^{10,19}, Ziv Gan-Or ^{1,2,3}

¹Montreal Neurological Institute, McGill University, Montréal, QC, Canada

²Department of Human Genetics, McGill University, Montréal, QC, Canada

³Department of Neurology and neurosurgery, McGill University, Montréal, QC, Canada

⁴Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.

⁵Oxford Parkinson's Disease Centre (OPDC), University of Oxford, Oxford, United Kingdom.

⁶Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, United Kingdom.

⁷Sleep Disorders Unit, Pitié Salpêtrière Hospital, Centre de Recherche de l'Institut du Cerveau et de la Moelle Epinière and Sorbonne Universities, Paris, France.

⁸National Reference Center for Narcolepsy, Sleep Unit, Department of Neurology, Gui-de-Chauliac Hospital, CHU Montpellier, University of Montpellier, Inserm U1061, Montpellier, France.

⁹Sleep Disorders Clinic, Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria.

¹⁰Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, USA

¹¹University Lille North of France, Department of Clinical Neurophysiology and Sleep Center, CHU Lille, Lille, France.

¹²Sleep disorder Unit, Carémeau Hospital, University Hospital of Nîmes, France.

¹³Department of Biomedical and Neuromotor Sciences (DIBINEM), Alma Mater Studiorum,

University of Bologna, Bologna, Italy.

¹⁴IRCCS, Institute of Neurological Sciences of Bologna, Bologna, Italy.

¹⁵Department of Neurological Sciences, Università Vita-Salute San Raffaele, Milan, Italy.

¹⁶Department of engineering and medicine of innovation (DIMI), University of Verona, Italy

¹⁷Department of Sleep Medicine and Neuromuscular Disorders, University of Muenster, Germany.

¹⁸Department of Neurology, Mayo Clinic, Rochester, MN, USA.

¹⁹Neurodegenerative Diseases Research Unit, National Institute of Neurological Disorders and

Stroke, Bethesda, MD, USA

²⁰Sleep and Neurology Unit, Beau Soleil Clinic, Montpellier, France.

²¹EuroMov, University of Montpellier, Montpellier, France.

²²Paracelsus-Elena-Klinik, Kassel, Germany.

²³Department of Neurology, University Medical Centre Goettingen, Goettingen, Germany.

²⁴Department of Neurology, Philipps University, Marburg, Germany.

²⁵Department of Neurology and Centre of Clinical Neuroscience, Charles University, First

Faculty of Medicine and General University Hospital, Prague, Czech Republic.

²⁶Department of Medical Sciences and Public Health, Sleep Disorder Research Center, University of Cagliari, Cagliari, Italy.

²⁷Laboratory for Sleep Disorders, St. Dimpna Regional Hospital, Geel, Belgium.

²⁸Department of Neurology, St. Dimpna Regional Hospital, Geel, Belgium.

²⁹Clinical Neurology Unit, Department of Head and Neck, University Hospital of Udine, Udine, Italy

³⁰Department of Medicine (DMED), University of Udine, Udine, Italy

³¹Centre d'Études Avancées en Médecine du Sommeil, Hôpital du Sacré-Cœur de Montréal,

Montréal, QC, Canada.

³²Department of Psychology, Université du Québec à Montréal, Montreal, QC, Canada.

³³Department of Neurosciences, Université de Montréal, Montréal, QC, Canada.

³⁴Department of Psychiatry, Université de Montréal, Montréal, QC, Canada.

³⁵Royal Papworth Hospital NHS Trust, Cambridge, UK

³⁶Department of Pharmacology & Therapeutics and Centre de Recherche en Biologie Structurale,

McGill University, Montréal, Québec, Canada

³⁷Department of Neurology, University Hospital Antwerp, Edegem, Antwerp, Belgium.

³⁸University of Glasgow, Glasgow, United Kingdom

³⁹Queen Elizabeth University Hospital, Glasgow, United Kingdom

Corresponding author: Ziv Gan-Or Montreal Neurological Institute, McGill University 1033 Pine Avenue, West, Ludmer Pavilion, room 312 Montreal, QC, H3A 1A1, Phone: +1-514-398-5845 e-mail: ziv.gan-or@mcgill.ca

Abstract

Two recent studies suggested that the APOE ε 4 haplotype was associated with increased α synuclein pathology in cell and mouse models. Genetic variants in the SNCA region have strong association with Parkinson's disease (PD), Dementia with Lewy Bodies (DLB), and idiopathic REM Sleep Behavior Disorder (iRBD), while APOE is a genetic risk determinant for only DLB. To determine if genetic-level interactions between SNCA and APOE exists that can explain the protein-level association, we investigated the genotypic interaction of APOE and SNCA in cohorts of PD, DLB, and iRBD. We analyzed genome-wide association study (GWAS) data from 5,229 PD patients and 5,480 controls, 2,610 DLB patients and 1,920 controls, and 1,055 iRBD patients and 3,667 controls. We used logistic regression interaction models across all 3 cohorts independently between the 1) top GWAS signals of SNCA SNPs and APOE haplotypes, 2) SNP x SNP and 3-way SNP interaction across the entire coding region plus 200kb flanking each gene. No significant interactions were found to be associated with any of the synucleinopathies after correction for multiple testing. Our results do not support a role for genetic interactions between APOE and SNCA across PD, DLB, and iRBD. Since the tested genetic variants affect the expression and function of these proteins, it is likely that any interactions between them does not affect the risk of PD, DLB and iRBD.

Keywords: Parkinson's Disease, Synucleinopathies, Dementia with Lewy Bodies, REM Sleep Behavior Disorder, Alzheimer's Disease, APOE, SNCA, synuclein, epistasis

1. Introduction

Alpha-Synucleinopathy is an umbrella term to describe several neurodegenerative diseases that have a common defining pathological feature, characterized by neuronal or glial inclusions of aggregated alpha-synuclein, known as Lewy bodies, Lewy neurites or glial cytoplasmatic inclusions in the brain¹. Disorders that are collectively referred to as alpha-synucleinopathies include Parkinson's disease (PD), Dementia with Lewy Bodies (DLB) and multiple system atrophy (MSA). Furthermore, there is an increased presence of alpha-Synucleinopathy in the prodromal condition idiopathic/isolated REM sleep behavior disorder (iRBD), which can convert to either PD, DLB or MSA in more than 80% of cases².

Alpha-synuclein is encoded by the *SNCA* gene, and genetic variants in the *SNCA* locus are associated with PD, DLB and iRBD risk in genome-wide association studies (GWASs)³⁻⁸. Specifically, some variants of *SNCA* are strongly associated with PD (rs356182 and rs2870004), while others are associated with DLB (rs7681440 and rs7680557)^{7,9} and iRBD (rs2870004)¹⁰. The top *SNCA* association in PD is independent and different than the top associations in DLB⁷ and iRBD⁸, raising the hypothesis that there could be differential effects of *SNCA* variants on the expression of alpha-synuclein in different brain regions⁸.

Overlapping neuropathologic features associated with Alzheimer's disease (AD) are seen in the brains of many patients with PD^{11} and dementia including amyloid plaques composed of amyloid-beta (A β) plaques and neurofibrillary tangles containing the tau protein and may contribute to clinical features of disease^{12,13}.

Coding variants in apolipoprotein E (*APOE*) produce 3 common alleles, $\varepsilon 2$, $\varepsilon 3$, and $\varepsilon 4$. The $\varepsilon 4$ allele of *APOE* regulates lipid metabolism and cholesterol transport and known to be a major genetic risk determinant for sporadic, late-onset Alzheimer's Disease¹⁴ and Lewy Body

Dementia^{7,9}. Dose effects by allele have demonstrated a 3.7-fold risk of developing AD while homozygosity increases the risk by up to 12-fold⁷. From numerous GWASs, A*POE* does not alter the risk for PD, yet the ε 4 allele has been described as a potential risk factor for cognitive decline and development of dementia in PD patients^{15,16}.

Two studies in mice demonstrated that the APOE* ε 4 genotype was associated with increased alpha-synuclein pathology, independent of the amyloid β deposition^{17,18}. These two studies emphasize a potential molecular mechanism of APOE* ε 4 on α -Synuclein protein aggregation. However, beyond A53T, they have not evaluated disease specific variants of *SNCA* that have functional molecular consequences (*e.g.* E46K)¹⁹. Analysis of these variants could be insightful in understanding molecular association between *SNCA* variants and APOE* ε 4. Furthermore, while the *SNCA* locus is associated with all synucleinopathies, *APOE* is a genetic risk factor for DLB only. *SNCA* and *APOE* variants may affect the expression / function of the proteins encoded by them²⁰. Therefore, if a true interaction exists at the protein level as suggested by the studies mentioned above, then there plausibly should be evidence of some association at the genetic level.

Genetic interactions refer to a combination of two or more genetic variants whose phenotypic contribution is amplified by their co-occurrence²¹. To determine if genetic-level interactions between *SNCA* and *APOE* exist that can explain the protein-level association as described, we investigated the genotypic interaction of *APOE* and *SNCA* in three disease cohorts of PD, DLB and iRBD patients and controls, with a total of 8,855 patients and 11,067 controls.

2. Methods

Patient population: For PD, we used the International Parkinson's Disease Genomics Consortium (IPDGC) data set that contained 10,709 subjects with 5,229 cases and 5,480 controls. For DLB, we used the most recent DLB GWAS dataset which included 4,530 subjects with 2,610 cases and 1,920 controls. The iRBD cohort was composed of 4,742 individuals, including 1,055 cases and 3,667 controls with 1,968 controls from NGRC, (dbGAP: phs000196.v2.p1) and 790 controls from NIND (dbGAP: phs000089) added from external studies of Parkinson's patients in addition to the controls collected for the iRBD cohort. PD was diagnosed using UK Brain Bank criteria or Movement Disorders Society (MDS) criteria⁴. DLB patients were diagnosed with pathologically definite or clinically probable disease according to consensus criteria²². iRBD was diagnosed according to the International Classification of Sleep Disorders (2nd or 3rd Edition)^{23,24}. Informed consent and ethics approval was obtained from the appropriate institutional review boards at participating institutions as described in the original studies.

Genetic Analysis: We generated genotype calls of two *APOE* SNPs, rs429358 and rs7412 to determine the *APOE* haplotype status of each sample. The combination of genotypes for rs429358 (C/T) and rs7412 (C/T) defines the three *APOE* haplotypes: epsilon 2 (ϵ 2), epsilon 3 (ϵ 3), and epsilon 4 (ϵ 4). These three haplotypes can produce six genotypes, ϵ 2/ ϵ 2, ϵ 2/ ϵ 3, ϵ 2/ ϵ 4, ϵ 3/ ϵ 3, ϵ 3/ ϵ 4, and ϵ 4/ ϵ 4, whose frequency amongst the cohorts is detailed in Table 2. Cohorts were collected, quality controlled, genotyped and filtered on individual and variant-level as previously described for PD⁴, iRBD⁸, and DLB⁷. *APOE* variants were analyzed for the 200kb region flanking both sides on chromosome 19: 44,705,791 - 45,109,393 and for

SNCA on chromosome 4: 89,500,345 - 90,038,324. For the iRBD cohort, additional cohorts of control subjects added from NIND and NGRC were included. The DLB genotypic data was converted from GrCh38 to GrCh37 using Liftover¹⁷. Because external controls were added to the iRBD cohort; the cases and control genotypes were filtered for minor allele frequency (MAF) > 0.01 to reduce imputation errors and imputed using Michigan Imputation Server and the Haplotype Reference Consortium¹⁸ r1.1 2016 reference panel (GRCh37/hg19). Only imputed genotypes with an $R^2 > 0.30$ were kept for analysis. Additionally, prior to analysis further quality control for each cohort included removing duplicate samples, missing data including covariates; SNPs were filtered based on variant missingness (< 0.05), genomic relatedness (> 0.125), disparate missingness between cases and controls (p > 1E-04), missingness by haplotype (p > 1E-04), deviation from Hardy-Weinberg equilibrium (p > 1E-04), minor allele frequency (MAF) > 0.01, and LD pruned with r² at >0.5 with a 50kb window using plink 1.9¹⁹.

Statistical Analysis: Descriptive measures of mean, standard deviations, frequencies, and percentages were used to summarize the data. SNP and haplotype interaction were analyzed using logistic regression controlling for age, sex and ancestry using the first five principal components. Epistasis model was defined as

$$Y \sim \beta_0 + \beta_1 A + \beta_2 B + \beta_3 A B + \epsilon$$

where β_0 represents the intercept, β_n represents the coefficients for each SNP, and A and B represent allele dosage of each SNP and AB represents the interaction. The test for interaction was based on the coefficient β_3 and P-value<0.05 as significant when testing interaction between top SNPs, and Bonferroni threshold applied for SNP x SNP interactions. Detecting

gene-gene interactions in complex diseases can be accomplished using a variety of epistasisfocused tools or packages in existing software packages. Model- based Multifactor Dimensionality Reduction (MB-MDR) was implemented as a final screen strategy to detect any significant SNP x SNP and SNP x SNP x SNP interactions using the open-source MB-MDR v 4.4.1 software, as MB-MDR merges multi-locus genotypes exhibiting some significant evidence of High or Low risk, based on association testing into a new lower-order dimension. A new association test is subsequently performed per marker pair/triplet, by adopting a permutation-based strategy that corrects for multiple testing (over all marker pairs/triplets) and adequately controls family-wise error rate at α =5%²⁰.

3. **Results**

To explore possible interactions between *APOE* and *SNCA* in cases and controls, we first focused primarily on the top *SNCA* SNPs associated with PD, DLB, and RDB (Table 1) and the *APOE* haplotypes. We performed a SNP-haplotype logistic regression interaction controlling for age, sex and ancestry using the first five principal components. No significant interactions were found to be statistically significant (Table 1).

To further explore all potential genetic interactions between *APOE* and *SNCA*, we expanded the range to include all SNPs in *APOE* and *SNCA* plus 200kb outside the region ends on both genes across all cohorts. We pruned SNPs that were in LD with an r^2 of 0.5 with 316 SNPs remaining in PD; 421 SNPs remaining in DLB; and 198 SNPs remaining in iRBD. We applied PLINKs regression-based approach to model and test SNP x SNP interactions. After correction for multiple comparisons with a Bonferroni correction, we did not identify any interactions associated with any of the alpha-synucleinopathies (Table 3).

Lastly, a model-based Multifactor Dimensionality Reduction method was implemented as a final screen strategy to detect any significant SNP x SNP and SNP x SNP x SNP interactions using the open-source MB-MDR software²¹. Here too, no significant interactions were found to be associated with PD, DLB or iRBD after correction for multiple testing using permutation testing across all three cohorts (Supplementary Tables S1-S3).

4. Discussion

Our results do not support a role for genetic interactions between *APOE* and *SNCA* across PD, DLB, and iRBD. The genetic variants that were tested influence the expression and function of these proteins, but it is unlikely that any interactions between them affect the risk of developing synucleinopathies. Although functional epistasis, in the form of biomolecular interaction, can determine biological pathways of disease progression, it may not always be detected through mathematical or statistical genetic interaction analyses. Furthermore, the genetic interactions identified in our study, which represent three synucleinopathies, do not support the pathological associations observed in model organisms intended to represent these disease populations.

Previous studies have shown that APOE ε 4 is linked to DLB in both AD and non-AD cases ^{22,23}. However, some studies have also shown that APO ε 4 is only associated with DLB when there is a significant amount of co-existing Alzheimer's pathology ²⁴⁻²⁶. This finding contradicts the idea that APO ε 4 independently drives α -synuclein pathology.

This study has several limitations. The lack of pathological confirmation of Lewy Bodies and AD pathology in the cohorts does not allow for an analysis based on co-pathology. Such analysis would have been able to detect interactions that exist only in subpopulation of patients, for example those who have both alpha-synuclein and amyloid pathology. Another limitation

is that the study scope was limited to *APOE* and *SNCA*. Recently, a stratified GWAS of DLB uncovered an association only between *GBA* rs2230288 and pathologically confirmed DLB without AD pathology, but not in mixed pathological cases ²⁶. This same SNP has been identified as a significant risk variant in the most recent GWAS of DLB ⁷. It is possible that large scale GWAS would uncover associations that encompass a broad spectrum of disease (e.g. DLB with no AD pathology, DLB with mixed PD and AD pathology etc.), even though these associations may be driven by subsets of these genetic loci (e.g *GBA*). Furthermore, it is plausible that different disease subtypes consist of distinct genetic combinations and interactions that have not yet been identified at a population level due to the limited size of current sample cohorts. Further studies should include more samples and implement alternative statistical or interrogative methods to leverage the current data to its fullest potential despite its small sample size.

Data Availability

The data that support the findings of this study are available from dbGaP. Parkinson's patients and controls (phs000918.v1.p1). DLB patients and controls are available from dbGaP (phs001963.v1.p1). iRBD patients and controls are available upon reasonable request from the corresponding author. Additional controls were also obtained from dbGaP; NGRC (phs000196.v2.p1) and NIND (phs000089). Code used for analysis can be found on GitHub (https://github.com/gan-orlab/APOE_SNCA)

Acknowledgements

We would like to thank all the participants in the different cohorts. We would also like to thank all members of the International Parkinson Disease Genomics Consortium (IPDGC). See for a complete overview of members, acknowledgements, and funding http://pdgenetics.org/partners.

Funding

This work was financially supported by the Michael J. Fox Foundation and the Canadian Consortium on Neurodegeneration in Aging (CCNA). GAR holds a Canada Research Chair in Genetics of the Nervous System and the Wilder Penfield Chair in Neurosciences. EAF is supported by a Foundation Grant from the Canadian Institutes of Health Research (FDN grant – 154301). ZGO is supported by the Fonds de recherche du Québec - Santé (FRQS) Chercheurs-boursiers award and is a William Dawson Scholar.

Competing Interests

Prabhjyot Saini - Nothing to declare

Eric Yu - Nothing to declare

Mehrdad A. Estiar - Nothing to declare

Lynne Krohn - Nothing to declare

Kheireddin Mufti - Nothing to declare

Uladzislau Rudakou - Nothing to declare

Jennifer A. Ruskey - Nothing to declare

Farnaz Asayesh - Nothing to declare

Sandra B. Laurent - Nothing to declare

Dan Spiegelman - Nothing to declare

Jean-François Trempe - Nothing to declare

Timothy G. Quinnell - Nothing to declare

Nicholas Oscroft - Nothing to declare

Isabelle Arnulf - I.A. was previously consultant for Idorsia pharma, and UCB Pharma.

Jacques Y. Montplaisir - Nothing to declare

Jean-François Gagnon - Jean-François Gagnon

Alex Desautels - Alex Desautels received operating grants from CHIR, AASM and research grants from Eisai, Takeda and Canopy Growth; honoraria from serving on the scientific advisory board of Eisai, Paladin Labs and UCB, as well as honoraria from speaking engagements from Eisai, Jazz Pharma and Paladin Labs. None of the financial disclosures is relevant to the submitted work.

Yves Dauvilliers - has served as a consultant or on advisory boards for Avadel Pharmaceuticals, Jazz Pharmaceuticals, UCB, Takeda Pharmaceutical Co., Theranexus, Harmony Biosciences, Bioprojet Pharma, and Idorsia

Gian Luigi Gigli - Nothing to declare Mariarosaria Valente - Nothing to declare Francesco Janes - Nothing to declare Andrea Bernardini - Nothing to declare Karel Sonka - Nothing to declare David Kemlink - Nothing to declare

Wolfgang Oertel - Wolfgang H. Oertel has received speaker's honoria on educational symposia sponsored by Abbvie, the International Movement Disorders Society and Stada Pharma. He acts as consultant for Lario Therapeutics and is a member of advisory boards with Intrabio and MODAG. He holds stock options with Intrabio not related to this manuscript and stock options with MODAG not related to this work. The institution of W.H.O., not W.H.O personally received/s scientific grants from the Stichting ParkinsonFonds The Netherlands, The ParkinsonFonds Germany related to this manuscript and scientific grants from the German Research Foundation, the Michael J Fox Foundation and the Rittal Foundation unrelated to the manuscript.

Annette Janzen -received grants from the ParkinsonFond Deutschland.

Giuseppe Plazzi – Has received consultancy fees for Bioprojet, Jazz, Takeda, Idorsia, Alkermes, and Centessa.

Elena Antelmi - Nothing to declare

Francesco Biscarini – Honorarium from BioProjet

Michela Figorilli – Nothing to declare

Monica Puligheddu - Nothing to declare

Brit Mollenhauer - Nothing to declare

Claudia Trenkwalder - Nothing to declare

Friederike Sixel-Döring - Nothing to declare

Valérie Cochen De Cock – Nothing to declare

Christelle Charley Monaca - Nothing to declare

Donald Grosset - Nothing to declare

Anna Heidbreder - Nothing to declare

Luigi Ferini-Strambi - Nothing to declare

Femke Dijkstra - Nothing to declare

Mineke Viaene - Nothing to declare

Beatriz Abril – Nothing to declare.

Bradley F. Boeve - Honorarium for SAB activities for the Tau Consortium - funded by the Rainwater Charitable Foundation; institutional research grant support for clinical trials from Alector, Transposon, Cognition Therapeutics, EIP Pharma; grant support from NIH, Lewy Body Dementia Association, American Brain Foundation, Mayo Clinic Dorothy and Harry T. Mangurian Jr. Lewy Body Dementia Program, the Little Family Foundation, the Ted Turner and Family Foundation

Ronald B. Postuma - R.B.P. reports grants and personal fees from Fonds de la Recherche en Sante, grants from Canadian Institute of Health Research, The Michael J. Fox Foundation (MJFF), the Webster Foundation, Roche, and the National Institute of Health and personal fees from Takeda, Biogen, AbbVie, Curasen, Lilly, Novartis, Eisai, Paladin, Merck, Vaxxinity, Korro, Bristol Myers Squibb and the International Parkinson and Movement Disorders Society, outside the submitted work.

Guy A. Rouleau - Nothing to declare

Abubaker Ibrahim - Nothing to declare

Ambra Stefani -Nothing to declare

Birgit Högl - Nothing to declare

Michele T.M. Hu - Nothing to declare

Sonja W. Scholz - S.W.S. serves on the scientific advisory board of the Lewy Body Dementia Association, Mission MSA, and G-Can. S.W.S. receives research support from Cerevel Therapeutics.

Ziv Gan-Or received consultancy fees from Lysosomal Therapeutics Inc. (LTI), Idorsia, Prevail Therapeutics, Ono Therapeutics, Denali, Handl Therapeutics, Neuron23, Bial Biotech, Bial, UCB, Capsida, Vanqua bio, Congruence Therapeutics, Takeda, Jazz pharmaceuticals, Guidepoint, Lighthouse and Deerfield

References

1. Calabresi P, Mechelli A, Natale G, Volpicelli-Daley L, Di Lazzaro G, Ghiglieri V. Alpha-synuclein in Parkinson's disease and other synucleinopathies: from overt neurodegeneration back to early synaptic dysfunction. *Cell Death Dis*. 2023/03/01 2023;14(3):176. doi:10.1038/s41419-023-05672-9

2. Postuma RB, Iranzo A, Hu M, *et al*. Risk and predictors of dementia and parkinsonism in idiopathic REM sleep behaviour disorder: a multicentre study. *Brain*. Mar 1 2019;142(3):744-759. doi:10.1093/brain/awz030

3. Foo JN, Chew EGY, Chung SJ, *et al*. Identification of Risk Loci for Parkinson Disease in Asians and Comparison of Risk Between Asians and Europeans: A Genome-Wide Association Study. *JAMA Neurology*. 2020;doi:10.1001/jamaneurol.2020.0428 %J JAMA Neurology

4. Nalls MA, Blauwendraat C, Vallerga CL, *et al.* Identification of novel risk loci, causal insights, and heritable risk for Parkinson's disease: a meta-analysis of genome-wide association studies. *The Lancet Neurology*. 2019;18(12):1091-1102. doi:10.1016/S1474-4422(19)30320-5

5. Nalls MA, Pankratz N, Lill CM, *et al*. Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson's disease. *Nat Genet*. 2014/09/01 2014;46(9):989-993. doi:10.1038/ng.3043

6. Chang D, Nalls MA, Hallgrímsdóttir IB, *et al*. A meta-analysis of genome-wide association studies identifies 17 new Parkinson's disease risk loci. *Nat Genet*. Oct 2017;49(10):1511-1516. doi:10.1038/ng.3955

7. Chia R, Sabir MS, Bandres-Ciga S, *et al*. Genome sequencing analysis identifies new loci associated with Lewy body dementia and provides insights into its genetic architecture. *Nat Genet*. Mar 2021;53(3):294-303. doi:10.1038/s41588-021-00785-3

8. Krohn L, Heilbron K, Blauwendraat C, *et al*. Genome-wide association study of REM sleep behavior disorder identifies novel loci with distinct polygenic and brain expression effects. 2021:2021.09.08.21254232. doi:10.1101/2021.09.08.21254232 %J medRxiv

9. Guerreiro R, Ross OA, Kun-Rodrigues C, *et al.* Investigating the genetic architecture of dementia with Lewy bodies: a two-stage genome-wide association study. *Lancet Neurol.* Jan 2018;17(1):64-74. doi:10.1016/s1474-4422(17)30400-3

10. Krohn L, Wu RYJ, Heilbron K, *et al*. Fine-Mapping of SNCA in Rapid Eye Movement Sleep Behavior Disorder and Overt Synucleinopathies. *Ann Neurol*. Apr 2020;87(4):584-598. doi:10.1002/ana.25687

11. Dugger BN, Adler CH, Shill HA, *et al*. Concomitant pathologies among a spectrum of parkinsonian disorders. *Parkinsonism Relat Disord*. May 2014;20(5):525-9. doi:10.1016/j.parkreldis.2014.02.012

12. Irwin DJ, Lee VM, Trojanowski JQ. Parkinson's disease dementia: convergence of α -synuclein, tau and amyloid- β pathologies. *Nat Rev Neurosci*. Sep 2013;14(9):626-36. doi:10.1038/nrn3549

13. Irwin DJ, White MT, Toledo JB, *et al*. Neuropathologic substrates of Parkinson disease dementia. *Ann Neurol*. Oct 2012;72(4):587-98. doi:10.1002/ana.23659

14. Serrano-Pozo A, Das S, Hyman BT. APOE and Alzheimer's disease: advances in genetics, pathophysiology, and therapeutic approaches. *Lancet Neurol*. Jan 2021;20(1):68-80. doi:10.1016/s1474-4422(20)30412-9

15. Morley JF, Xie SX, Hurtig HI, *et al*. Genetic influences on cognitive decline in Parkinson's disease. *Mov Disord*. Apr 2012;27(4):512-8. doi:10.1002/mds.24946

16. Pankratz N, Byder L, Halter C, *et al*. Presence of an APOE4 allele results in significantly earlier onset of Parkinson's disease and a higher risk with dementia. *Mov Disord*. Jan 2006;21(1):45-9. doi:10.1002/mds.20663

17. Kuhn RM, Haussler D, Kent WJ. The UCSC genome browser and associated tools. *Brief Bioinform*. Mar 2013;14(2):144-61. doi:10.1093/bib/bbs038

18. McCarthy S, Das S, Kretzschmar W, *et al*. A reference panel of 64,976 haplotypes for genotype imputation. *Nat Genet*. Oct 2016;48(10):1279-83. doi:10.1038/ng.3643

19. Purcell S, Neale B, Todd-Brown K, *et al*. PLINK: A Tool Set for Whole-Genome Association and Population-Based Linkage Analyses. *The American Journal of Human Genetics*. 2007;81(3):559-575. doi:10.1086/519795

20. Mahachie John JM, Van Lishout F, Van Steen K. Model-Based Multifactor Dimensionality Reduction to detect epistasis for quantitative traits in the presence of error-free and noisy data. *Eur J Hum Genet*. 2011/06/01 2011;19(6):696-703. doi:10.1038/ejhg.2011.17

21. Cattaert T, Calle ML, Dudek SM, *et al*. Model-Based Multifactor Dimensionality Reduction for detecting epistasis in case–control data in the presence of noise. 2011;75(1):78-89. doi:10.1111/j.1469-1809.2010.00604.x

22. Tsuang D, Leverenz JB, Lopez OL, *et al*. APOE ε4 increases risk for dementia in pure synucleinopathies. *JAMA Neurol*. Feb 2013;70(2):223-8. doi:10.1001/jamaneurol.2013.600

23. Dickson DW, Heckman MG, Murray ME, *et al*. APOE ε4 is associated with severity of Lewy body pathology independent of Alzheimer pathology. *Neurology*. Sep 18 2018;91(12):e1182-e1195. doi:10.1212/wnl.00000000006212

24. Prokopenko I, Miyakawa G, Zheng B, *et al.* Alzheimer's disease pathology explains association between dementia with Lewy bodies and APOE- ϵ 4/TOMM40 long poly-T repeat allele variants. *Alzheimer's & dementia (New York, N Y).* 2019;5:814-824. doi:10.1016/j.trci.2019.08.005

25. Schaffert J, LoBue C, White CL, 3rd, *et al*. Risk factors for earlier dementia onset in autopsyconfirmed Alzheimer's disease, mixed Alzheimer's with Lewy bodies, and pure Lewy body disease. *Alzheimer's & dementia : the journal of the Alzheimer's Association*. Mar 2020;16(3):524-530. doi:10.1002/alz.12049

26. Kaivola K, Shah Z, Chia R, Consortium ILG, Scholz SW. Genetic evaluation of dementia with Lewy bodies implicates distinct disease subgroups. *Brain*. 2021;145(5):1757-1762. doi:10.1093/brain/awab402 %J Brain

Demographic			Total		PD		DLB		iRBD
Sex	Cases	Male (%)	5845 (65.72)		3366 (64.37)		1642 (62.91)		837 (79.34)
		Female (%)	3010 (33.84)	-	1863 (35.63)	-	947 (36.28)		200 (18.96)
	Controls	Male (%)	7256 (65.56)		3055 (55.75)		972 (50.63)		1564 (42.65)
		Female (%)	3811 (34.44)		2425 (44.25)		948 (49.38)		2103 (57.34)
Age	Cases	65.7 (13.6)			61.2 (12.6)		74.7 (10.5)		-
	Controls		67.9 (16.2)		64.3 (14.8)		72.7 (16.8)		-

Table 1: Age and sex of each cohort in cases and controls.

Values for age represent mean and standard deviation in parenthesis. Age information for iRBD was missing Abbreviations: PD, Parkinson's Disease; DLB, Dementia with Lewy Bodies; iRBD, Idiopathic Rapid Eye Movement (REM) sleep behavior disorder.

Group	Haplotype	Controls	Cases	Total	
DLB	e2e2	4 (.21)	5 (.19)	9	
	e2e3	171 (8.91)	189 (4.17)	360	
	e2e4	17 (.89)	83 (3.18)	100	
	e3e3	1273 (66.30)	1203 (46.09)	2476	
	e3e4 419 (21.82) 916 (35.10)		916 (35.10)	1335	
	e4e4	36 (1.88)	214 (8.20)	250	
	Total	1920 (42.38)	2610 (57.62)	4530	
	e2e2	22 (.61)	5 (.48)	27	
	e2e3	444 (12.27)	109 (10.4)	553	
	e2e4	82 (2.27)	15 (1.43)	97	
irrd	e3e3	2241 (61.92)	671 (64.03)	2912	
mee	e3e4	752 (20.78)	236 (22.52)	988	
	e4e4	78 (2.16)	12 (1.15)	90	
	Total	3619 (77.54)	1048 (22.46)	4667	

Table 2: APOE Haplotype Frequencies of each cohort in cases and controls

	Total	5480 (51.17)	5229 (48.83)	10709	
PD	e4e4	55 (1.00)	43 (.82)	98	
	e3e4	954 (17.41)	932 (17.82)	1886	
	e3e3	3599 (65.68)	3498 (66.90)	7097	
	e2e4	106 (1.93)	75 (1.43)	181	
	e2e3	725 (13.23)	656 (12.55)	1381	
	e2e2	41 (.75)	25 (.48)	66	

Values represent frequency and percentage.

Abbreviations: PD, Parkinson's Disease; DLB, Dementia with Lewy Bodies; iRBD, Idiopathic Rapid Eye Movement (REM) sleep behavior disorder.

Disease	Gene	Chr	Location	Ref Allele	Alt Allele	rs		Estimate	Standard Error	z-score	Pr(> z)
iRBD	SNCA	4	90471245	т	А	rs2870004	rs2870004 x <i>APOE</i> Haplotype Interaction	-0.06359	0.06976	-0.912	0.362
		4	90626111	G	А	rs356182	rs356182 x <i>APOE</i> Haplotype Interaction	0.03883	0.0629	0.617	0.537021
		4	90756550	С	G	rs7681440	rs7681440 - <i>APOE</i> Haplotype Interaction	0.04838	0.05954	0.812	0.416257
PD	SNCA	4	90471245	т	А	rs2870004	rs2870004 x <i>APOE</i> Haplotype Interaction	0.039526	0.038801	1.019	0.30835
		4	90626111	G	А	rs356182	rs356182 x APOE Haplotype Interaction	0.027522	0.031979	0.861	0.389447
		4	90756550	С	G	rs7681440	rs7681440 - <i>APOE</i> Haplotype Interaction	- 0.016695	0.030556	-0.546	0.584807
DLB	SNCA	4	89550094	Т	А	rs2870004	rs2870004 x <i>APOE</i> Haplotype Interaction	- 0.139925	0.118107	-1.185	0.2361
		4	89704960	G	А	rs356182	rs356182 x <i>APOE</i> Haplotype Interaction	0.152286	0.110879	1.373	0.17
		4	89835399	С	G	rs7681440	rs7681440 - <i>APOE</i> Haplotype Interaction	0.070889	0.100602	0.705	0.481
Abbreviations: PD, Parkinson's Disease; DLB, Dementia with Lewy Bodies; iRBD, Idiopathic Rapid Eye Movement (REM) sleep behavior disorder.											

 Table 3: Top Hits of SNCA and APOE Haplotype Interaction Regression Results